Swiss National Bank
ALLO icon

Swiss National Bank’s Allogene Therapeutics ALLO Stock Holding History

Swiss National Bank’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-287,900
Closed -$613K – 2399
2024
Q4 		$613K Buy
287,900
+23,000
+9% +$56.7K ﹤0.01% 2365
2024
Q3 		$742K Sell
264,900
-22,100
-8% -$58.9K ﹤0.01% 2336
2024
Q2 		$669K Buy
287,000
+72,200
+34% +$213K ﹤0.01% 2345
2024
Q1 		$960K Hold
214,800
– – ﹤0.01% 2244
2023
Q4 		$690K Buy
214,800
+22,400
+12% +$63.5K ﹤0.01% 2411
2023
Q3 		$610K Buy
192,400
+5,600
+3% +$24.5K ﹤0.01% 2459
2023
Q2 		$928K Hold
186,800
– – ﹤0.01% 2331
2023
Q1 		$923K Sell
186,800
-21,600
-10% -$139K ﹤0.01% 2300
2022
Q4 		$1.31M Buy
208,400
+4,100
+2% +$38K ﹤0.01% 2173
2022
Q3 		$2.21M Buy
204,300
+2,500
+1% +$34K ﹤0.01% 1806
2022
Q2 		$2.3M Buy
201,800
+16,400
+9% +$146K ﹤0.01% 1815
2022
Q1 		$1.69M Buy
185,400
+13,400
+8% +$140K ﹤0.01% 2128
2021
Q4 		$2.57M Hold
172,000
– – ﹤0.01% 1893
2021
Q3 		$4.42M Buy
172,000
+1,500
+0.9% +$35.6K ﹤0.01% 1550
2021
Q2 		$4.45M Buy
170,500
+26,300
+18% +$750K ﹤0.01% 1583
2021
Q1 		$5.09M Buy
144,200
+2,500
+2% +$84.3K ﹤0.01% 1454
2020
Q4 		$3.58M Buy
141,700
+13,900
+11% +$453K ﹤0.01% 1569
2020
Q3 		$4.82M Buy
127,800
+2,400
+2% +$90.5K ﹤0.01% 1191
2020
Q2 		$5.37M Buy
125,400
+78,100
+165% +$2.82M ﹤0.01% 1106
2020
Q1 		$920K Buy
47,300
+700
+2% +$16.7K ﹤0.01% 1876
2019
Q4 		$1.21M Buy
46,600
+1,400
+3% +$38.6K ﹤0.01% 2028
2019
Q3 		$1.23M Hold
45,200
– – ﹤0.01% 1950
2019
Q2 		$1.21M Buy
+45,200
New +$1.26M ﹤0.01% 2009

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Swiss National Bank's ALLO Position: Q1 2025 in Review

Swiss National Bank sold out of Allogene Therapeutics (ALLO) in Q1 2025, closing a stake of 287,900 shares — an estimated $613K sold.

Swiss National Bank first reported a position in ALLO in Q2 2019 and held it in 23 quarters. The position peaked at $5.37M in Q2 2020. 170 funds tracked by Wall St. Rank hold ALLO as of Q1 2025.

  • Swiss National Bank reported no remaining Allogene Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Swiss National Bank sold 287,900 Allogene Therapeutics shares in Q1 2025, an estimated $613K.
  • Swiss National Bank first reported a position in Allogene Therapeutics in Q2 2019 and held it in 23 quarters.
  • Swiss National Bank's Allogene Therapeutics position peaked at $5.37M in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2025.

Based on Swiss National Bank's 13F filing for Q1 2025, filed 12 May 2025.